Dynamics of parasite clearance in cutaneous leishmaniasis patients treated with miltefosine

PLoS Neglected Tropical Diseases

Volumn 5, Issue 12, 2011, Pages

  Dorlo, Thomas P C ^a,b   van Thiel, Pieter P A M ^a   Schoone, Gerard J ^c   Stienstra, Ymkje ^a,d   van Vugt, Michèle ^a   Beijnen, Jos H ^b   de Vries, Peter J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c ROYAL TROPICAL INSTITUTE   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; MILTEFOSINE; ANTIPROTOZOAL AGENT; DRUG DERIVATIVE; PHOSPHORYLCHOLINE;

ACNE; ADULT; ARTHRALGIA; ARTICLE; CASE REPORT; CLINICAL ASSESSMENT; DIARRHEA; DRUG EFFECT; FEMALE; HUMAN; HUMAN TISSUE; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; LEISHMANIA MAJOR; MALE; PARASITE CLEARANCE; PARASITE LOAD; SKIN BIOPSY; SKIN DEFECT; SKIN LEISHMANIASIS; SKIN ULCER; STAPHYLOCOCCUS INFECTION; TREATMENT INDICATION; VOMITING; WEGENER GRANULOMATOSIS; ISOLATION AND PURIFICATION; MIDDLE AGED; PARASITOLOGY; SKIN;

ANTIPROTOZOAL AGENTS; FEMALE; HUMANS; LEISHMANIA INFANTUM; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MALE; MIDDLE AGED; PARASITE LOAD; PHOSPHORYLCHOLINE; SKIN;

EID: 84855269249     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001436     Document Type: Article

References (16)

1. Matlashewski G, Arana B, Kroeger A, Battacharya S, Sundar S, et al. (2011) Visceral leishmaniasis: elimination with existing interventions. Lancet Infect Dis 11: 322-325 doi:10.1016/S1473-3099(10)70320-0.
2. Chrusciak-Talhari A, Dietze R, Chrusciak Talhari C, da Silva RM, Gadelha Yamashita EP, et al. (2011) Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil. Am J Trop Med Hyg 84: 255-260 doi:10.4269/ajtmh.2011.10-0155.
3. Mohebali M, Fotouhi A, Hooshmand B, Zarei Z, Akhoundi B, et al. (2007) Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. Acta Trop 103: 33-40 doi:10.1016/j.actatropica.2007.05.005.
4. van Thiel PPAM, Leenstra T, Kager PA, de Vries HJ, van Vugt M, et al. (2010) Miltefosine treatment of Leishmania major infection: an observational study involving Dutch military personnel returning from northern Afghanistan. Clin Infect Dis 50: 80-83 doi:10.1086/648726.
5. Stojkovic M, Junghanss T, Krause E, Davidson RN, (2007) First case of typical Old World cutaneous leishmaniasis treated with miltefosine. Int J Dermatol 46: 385-387 doi:10.1111/j.1365-4632.2007.03153.x.
6. Keynan Y, Larios OE, Wiseman MC, Plourde M, Ouellette M, et al. (2008) Use of oral miltefosine for cutaneous leishmaniasis in Canadian soldiers returning from Afghanistan. Can J Infect Dis Med Microbiol 19: 394-396.
7. Dorlo TPC, van Thiel PPAM, Huitema ADR, Keizer RJ, de Vries HJC, et al. (2008) Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. Antimicrob Agents Chemother 52: 2855-2860 doi:10.1128/AAC.00014-08.
8. van der Meide W, Guerra J, Schoone G, Farenhorst M, Coelho L, et al. (2008) Comparison between quantitative nucleic acid sequence-based amplification, real-time reverse transcriptase PCR, and real-time PCR for quantification of Leishmania parasites. J Clin Microbiol 46: 73-78 doi:10.1128/JCM.01416-07.
9. Marfurt J, Nasereddin A, Niederwieser I, Jaffe CL, Beck HP, et al. (2003) Identification and Differentiation of Leishmania Species in Clinical Samples by PCR Amplification of the Miniexon Sequence and Subsequent Restriction Fragment Length Polymorphism Analysis. J Clin Microbiol 41: 3147-3153 doi:10.1128/JCM.41.7.3147-3153.2003.
10. van Thiel PPAM, van Gool T, Kager PA, Bart A, (2010) First Cases of Cutaneous Leishmaniasis Caused by Leishmania (Viannia) naiffi Infection in Surinam. Am J Trop Med Hyg 82: 588-590 doi:10.4269/ajtmh.2010.09-0360.
11. Dorlo TPC, Hillebrand MJX, Rosing H, Eggelte TA, de Vries PJ, et al. (2008) Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 865: 55-62 doi:10.1016/j.jchromb.2008.02.005.
12. del Giudice P, Marty P, Lacour JP, Perrin C, Pratlong F, et al. (1998) Cutaneous leishmaniasis due to Leishmania infantum. Case reports and literature review. Arch Dermatol 134: 193-198.
13. Pau M, Atzori L, Aste N, Aste N, (2009) Two cases of primary endonasal leishmaniasis in Sardinia (Italy). Dermatol Online J 15: 5.
14. Richter J, Hanus I, Häussinger D, Löscher T, Harms G, (2011) Mucosal Leishmania infantum infection. Parasitol Res 109: 959-962 doi:10.1007/s00436-011-2356-x.
15. de Vries PJ, van der Meide WF, Godfried MH, Schallig HDFH, Dinant HJ, et al. (2006) Quantification of the response to miltefosine treatment for visceral leishmaniasis by QT-NASBA. Trans R Soc Trop Med Hyg 100: 1183-1186 doi:10.1016/j.trstmh.2006.01.002.
16. Escobar P, Matu S, Marques C, Croft SL, (2002) Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B. Acta Trop 81: 151-157 doi:10.1016/S0001-706X(01)00197-8.